中文
Home > Brands > Multimedia > In the New Era
中文

  • On Oct 10, 2019, China Traditional Chinese Medicine Holdings Co Ltd held a press conference to release its SINO-TCM brand.

  • A photo taken on Dec 4, 2019 shows the opening ceremony of the 82nd PharmChina.

  • In 2020, Sinopharm CNBG proposed a treatment plan and technical standards for using convalescent plasma from recovered COVID-19 patients to cure critical patients, sparking a nationwide trend of convalescent plasma donation.

  • In 2020, the China State Institute of Pharmaceutical Industry worked hard to control the COVID-19 pandemic with solidarity and cooperation. The photo shows researchers from the Shanghai Institute of Pharmaceutical Industry conducting technical research on anti-COVID-19 drugs.

  • On Jan 10, 2020, Shanghai GeneoDx Biotech Co Ltd, an affiliate of Sinopharm CNBG, successfully developed the nation's first COVID-19 nucleic acid testing kit within 48 hours, contributing to the frontline efforts against the pandemic.

  • On Jan 23, 2020, Liu Jingzhen, commander-in-chief of the Sinopharm COVID-19 emergency supply headquarters, held an overnight emergency supply meeting for medical reserve materials at CMDC.

  • A photo taken on Jan 24, 2020 shows Liu Jingzhen, Sinopharm chairman and secretary of the CPC Sinopharm committee, along with Deputy General Manager Hu Jianwei, inspecting the Beijing Logistics Center of CMDC under Sinopharm Holding.

  • On Jan 28, 2020, Sinopharm North Hospital sent a medical team to Wuhan, Hubei province, to help with the fight against the coronavirus.

  • On Jan 30, 2020, Sinopharm Holding swiftly coordinated the inter-provincial transfer of medical supplies to Wuhan, Hubei province, playing a crucial role in safeguarding the lives and health of the people.

  • A photo taken in February 2020 shows Sinopharm's Dongfeng General Hospital using hyperbaric oxygen therapy to treat COVID-19 patients.

  • A photo taken in February 2020 shows frontline medical workers from Sinopharm Healthcare engaging in the treatment of COVID-19 patients in Wuhan, Hubei province.

  • Wuhan Institute of Biological Products Co Ltd under Sinopharm CNBG officially launched inactivated COVID-19 vaccines on Feb 28, 2020.

  • The Joint Prevention and Control Mechanism for COVID-19 under the State Council held a press conference in Beijing on April 8, 2020. Sinopharm Chairman and Secretary of the CPC Sinopharm Committee Liu Jingzhen attended the conference and answered questions raised by reporters.

  • On April 12, 2020, the Wuhan Institute of Biological Products under Sinopharm CNBG became the world's first facility to receive Phase I and II clinical trial approval for inactivated COVID-19 vaccines.

  • On April 27, 2020, the inactivated COVID-19 vaccines developed by Sinopharm CNBG's Beijing Institute of Biological Products received clinical trial approval from the National Medical Products Administration.

  • China's first BSL-3 laboratory for COVID-19 vaccine development was completed at Wuhan Institute of Biological Products on July 1, 2020.

1 2 3 ... 5 >

Address: Sinopharm Plaza, No 20 Zhichun Road, Haidian district, Beijing

Postcode: 100191

Tel: 86-10-82287727

Fax: 86-10-62033332

Links:
Search
Copyright ©  China National Pharmaceutical Group Co Ltd. All rights reserved. Presented by China Daily. 京公网安备 11040102700104号 京ICP备：14023670号-1
Links:
Contact Us

Address: Sinopharm Plaza, No 20 Zhichun Road, Haidian district, Beijing

Postcode: 100191 Tel: 86-10-82287727

Fax: 86-10-62033332

Copyright ©  China National Pharmaceutical Group Co Ltd.
All rights reserved. Presented by China Daily. 京公网安备 11040102700104号
京ICP备：14023670号-1